Current Trials Open to Accrual
Gastrointestinal Cancer
As of 6/17/2016

Liver
RTOG 1112: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma (UIC IRB# 2013-0486)

BA2011/03/04: Multicentre, randomized, controlled, open-label study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin Transdrug (DT) (20mg/m2 or 30mg/m2) to those of Best Standard of Care (BSC) in patients with advanced Hepatocellular Carcinoma (HCC) after failure or intolerance to Sorafenib. ReLive Study

Pancreatic
PCRT MM-141-07-02-02: A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 plus Nab-Paclitaxel and Gemcitabine versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer (UIC IRB# 2015-0966)

Rectal
N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (UIC IRB# 2013-0243)

PHASE I STUDIES – MULTIPLE DISEASE SITES
STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGFR (UIC IRB# 2013-0655)
STM-03: Phase I Study of PAC-1 in the Treatment of Advanced Hematologic Malignancy or Solid Tumors (UIC IRB #2015-0057
STM-04: A Phase I Study of rSIFN-co for Subjects with Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity (UIC IRB#2015-0807)
C14019: Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

For screening potential patients, please call:
ALBERTO CABRALES, CCRP
Phone: 3-1902
In-House Pager:  136-8094
Email: acabrales@uic.edu